Cargando…
Trial watch: intratumoral immunotherapy
While chemotherapy and radiotherapy remain the first-line approaches for the management of most unresectable tumors, immunotherapy has emerged in the past two decades as a game-changing treatment, notably with the clinical success of immune checkpoint inhibitors. Immunotherapies aim at (re)activatin...
Autores principales: | Humeau, Juliette, Le Naour, Julie, Galluzzi, Lorenzo, Kroemer, Guido, Pol, Jonathan G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526014/ https://www.ncbi.nlm.nih.gov/pubmed/34676147 http://dx.doi.org/10.1080/2162402X.2021.1984677 |
Ejemplares similares
-
Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020) -
Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020) -
Trial watch: TLR3 agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020) -
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020) -
Trial watch: dietary interventions for cancer therapy
por: Lévesque, Sarah, et al.
Publicado: (2019)